Par Pharmaceutical Inc. (mgc)
There are currently no manufacturer details available.
Share This Page
Par Pharmaceutical Inc. (mgc) Drugs
Calcitonin Salmon Spray
The recommended dose of Calcitonin Salmon Nasal Solution in postmenopausal osteoporotic females is one spray (200 International Unit) per day administered intranasally, alternating nostrils daily.
Drug effect may be monitored by periodic measurements of lumbar vertebral bone mass to document stabilization of bone loss or increases in bone density. Effects of Calcitonin Salmon Nasal Solution on biochemical markers of bone turnover have not been consistently demonstrated in studies in postmenopausal osteoporosis. Therefore, these parameters should not be solely utilized to determine clinical response to Calcitonin Salmon Nasal Solution therapy in these patients.
Priming (Activation) of Pump
Before the first dose and administration, Calcitonin Salmon Nasal Solution should be at room temperature. To prime the pump, the bottle should be held upright and the two white side arms of the pump depressed toward the bottle until a full spray is produced. The pump is primed once the first full spray is emitted. To administer, the nozzle should be carefully placed into the nostril with the head in the upright position, and the pump firmly depressed toward the bottle. The pump should not be primed before each daily dose.
Sign Up for a Free Account